What drugs does NOVITIUM PHARMA make?

NOVITIUM PHARMA has 105 FDA-approved drugs including INZIRQO, LEVOCARNITINE SF, SOVUNA.

What therapeutic areas does NOVITIUM PHARMA focus on?

NOVITIUM PHARMA focuses primarily on Cardiovascular and Infectious Disease and 1 other therapeutic areas.

Data updated: Nov 8, 2026

NOVITIUM PHARMA

Generics

Cardiovascular Infectious Disease Gastroenterology

NOVITIUM PHARMA is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Gastroenterology. Key products include INZIRQO.

1971

Since

105

Drugs

Trials

New Drugs (2yr)

Modality:

3 Small Molecules

NOVITIUM PHARMA's Key Drugs

NOVITIUM PHARMA's core commercial portfolio centers on INZIRQO, LEVOCARNITINE SF, SOVUNA, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.

Hypertension

Carnitine Deficiency

Malaria

FINASTERIDE AND TADALAFIL

Urology

Approved 2024

NOVITIUM PHARMA's Recent FDA Approvals

NOVITIUM PHARMA secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

NOVITIUM PHARMA's Therapeutic Areas

NOVITIUM PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 27%

9 drugs

Infectious Disease 21%

7 drugs

Gastroenterology 21%

7 drugs

Immunology 15%

5 drugs

Neurology 15%

5 drugs

NOVITIUM PHARMA's Top Competitors

NOVITIUM PHARMA's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and WARNER CHILCOTT. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Bristol-Myers Squibb big-pharma

Immunology, Infectious Disease, Gastroenterology, Neurology

Pfizer big-pharma

Infectious Disease, Immunology, Neurology

WARNER CHILCOTT big-pharma

Cardiovascular, Gastroenterology, Neurology, Infectious Disease, Immunology

APOTHECON specialty

Infectious Disease, Cardiovascular, Gastroenterology, Immunology

Novo Nordisk big-pharma

Immunology, Cardiovascular, Infectious Disease, Neurology